I-Mab (IMAB) announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech. The transaction provides I-Mab with the rights to bispecific and multi-specific applications, based on the Claudin 18.2 parental antibody used in the Company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig. Under the terms of the agreement, I-Mab will pay Bridge Health shareholders an upfront payment of $1.8 million and non-contingent payments of $1.2 million through 2027. In addition, Bridge Health shareholders may receive future milestone payments of up to $3.875 million, subject to the achievement of certain development and regulatory milestones. The transaction is expected to close in Q3 of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-MAB Amends Prospectus for $21 Million ADS Offering
- I-MAB’s Givastomig Shows Promising Efficacy and Safety in Gastric Cancer, Earning Buy Rating
- Promising Clinical Developments and Strong Performance Drive Buy Rating for I-MAB
- I-Mab Reports Promising Phase 1b Results for Givastomig in Gastric Cancer
- I-Mab presents Gibastomig Phase 1b dose escalation data